Abstract
Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue. This chapter summarizes the key requirements for polymers used in the DES, including physical properties, stability, compatibility with drugs, biocompatibility with vascular tissue and control of drug release. An in-depth analysis of polymer structure, coating design, drug-polymer morphology and drug elution profile is provided for the four currently marketed DES: CYPHER® Sirolimus- eluting Coronary Stent, Taxus® / Taxus Liberte®, XIENCE V™ / Promus® and Endeavor®. A new generation of DES is being developed using bioabsorbable polymers which degrade over time and leave behind a bare metal stent. This includes the RES TECHNOLOGY™ platform employed in the NEVO™ Sirolimus-eluting Coronary Stent which is explored with respect to polymer composition, degradation profile and drug release kinetics.
Keywords: Polymers, Eluting Stents, drug-polymer morphology, local drug delivery, biostable, bioabsorbable, drug delivery, stent, restenosis, coronary angioplasty, neointimal hyperplasia, bare metal stent, sterilization, cobalt chromium alloy, poly(butyl methacrylate), PBMA, ethylene oxide, esters, amides, anhydrides, reendothelialization, Cypher, Xience V, Promus, Endeavor, Parylene C, Sirolimus, isobutylene, styrene, oxidation, SIBS phase, PVDF-HFP, methacrylated phosphorylcholine, lauryl methacrylate, hydroxypropyl methacrylate, trimethylsilyl methacrylate, polyorthoesters, DL-lactide, glycolide, ethylene glycol
Current Pharmaceutical Design
Title: Polymers for Drug Eluting Stents
Volume: 16 Issue: 36
Author(s): Ted Parker, Vipul Dave and Robert Falotico
Affiliation:
Keywords: Polymers, Eluting Stents, drug-polymer morphology, local drug delivery, biostable, bioabsorbable, drug delivery, stent, restenosis, coronary angioplasty, neointimal hyperplasia, bare metal stent, sterilization, cobalt chromium alloy, poly(butyl methacrylate), PBMA, ethylene oxide, esters, amides, anhydrides, reendothelialization, Cypher, Xience V, Promus, Endeavor, Parylene C, Sirolimus, isobutylene, styrene, oxidation, SIBS phase, PVDF-HFP, methacrylated phosphorylcholine, lauryl methacrylate, hydroxypropyl methacrylate, trimethylsilyl methacrylate, polyorthoesters, DL-lactide, glycolide, ethylene glycol
Abstract: Currently approved drug eluting stents (DES) consist of a metallic scaffold and an elutable drug dispersed in a polymer matrix that conformally surrounds the struts. These primarily biostable polymers bind the drug to the stent and modulate the elution of the drug into the arterial tissue. This chapter summarizes the key requirements for polymers used in the DES, including physical properties, stability, compatibility with drugs, biocompatibility with vascular tissue and control of drug release. An in-depth analysis of polymer structure, coating design, drug-polymer morphology and drug elution profile is provided for the four currently marketed DES: CYPHER® Sirolimus- eluting Coronary Stent, Taxus® / Taxus Liberte®, XIENCE V™ / Promus® and Endeavor®. A new generation of DES is being developed using bioabsorbable polymers which degrade over time and leave behind a bare metal stent. This includes the RES TECHNOLOGY™ platform employed in the NEVO™ Sirolimus-eluting Coronary Stent which is explored with respect to polymer composition, degradation profile and drug release kinetics.
Export Options
About this article
Cite this article as:
Parker Ted, Dave Vipul and Falotico Robert, Polymers for Drug Eluting Stents, Current Pharmaceutical Design 2010; 16 (36) . https://dx.doi.org/10.2174/138161210794454897
DOI https://dx.doi.org/10.2174/138161210794454897 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Angiotensin Converting Enzyme Inhibitory Peptides Derived from Food Proteins: Biochemistry, Bioactivity and Production
Current Pharmaceutical Design Autophagy and Ubiquitination as Two Major Players in Colorectal Cancer: A Review on Recent Patents
Recent Patents on Anti-Cancer Drug Discovery Regional Distribution and Kinetics of Inhaled Pharmaceuticals
Current Pharmaceutical Design CD164 as a Basophil Activation Marker
Current Pharmaceutical Design Anticancer Activities of New N-hetaryl-2-cyanoacetamide Derivatives Incorporating 4,5,6,7-Tetrahydrobenzo[b]thiophene Moiety
Anti-Cancer Agents in Medicinal Chemistry Manganese Enhanced Magnetic Resonance Imaging
Current Pharmaceutical Biotechnology Human Kallikreins: Common Structural Features, Sequence Analysis and Evolution
Current Genomics Food and Food Supplements with Hypocholesterolemic Effects
Recent Patents on Food, Nutrition & Agriculture In vivo Monitoring of Oxygen Levels in Human Brain Tumor Between Fractionated Radiotherapy Using Oxygen-enhanced MR Imaging
Current Medical Imaging Magnetite Nanostructures with Applications in Cancer Therapy
Current Proteomics Nanoparticle-Based Tumor Theranostics with Molecular Imaging
Current Pharmaceutical Biotechnology Tumor-Intrinsic and Tumor-Extrinsic Factors Impacting Hsp90- Targeted Therapy
Current Molecular Medicine Bone Changes in Patients with Inflammatory Arthritis Treated with Biological Therapies: A Clinical Perspective
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Interleukin-6 In Rheumatoid Arthritis - From The Laboratory To The Bedside
Current Pharmaceutical Design Dipeptidyl Peptidase-4 Inhibition: Linking Chemical Properties to Clinical Safety
Current Medicinal Chemistry Recent Developments to Improve the Efficacy of Cytotoxic Nucleoside Analogues
Recent Patents on Anti-Cancer Drug Discovery Tumor-Specific Delivery of Histidine-Rich Glycoprotein Suppresses Tumor Growth and Metastasis by Anti-angiogenesis and Vessel Normalization
Current Gene Therapy Targeting Chemokine Receptor CXCR4 for Treatment of HIV-1 Infection, Tumor Progression, and Metastasis
Current Topics in Medicinal Chemistry Design and Synthesis Three Steroid-Tetraone Derivatives Using Testosterone as Chemical Tool
Letters in Organic Chemistry Tamoxifen and its New Derivatives in Cancer Research
Recent Patents on Anti-Cancer Drug Discovery